A Double Dose of Doxil: FDA Advisory Committee Will Review Two Applications
This article was originally published in The Pink Sheet Daily
Executive Summary
Centocor’s Yondelis application for relapsed ovarian cancer is the headliner for the July 15 ODAC meeting, but the cardiac safety profile of Doxil could take center stage.